<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02997748</url>
  </required_header>
  <id_info>
    <org_study_id>04-AnIt-16</org_study_id>
    <nct_id>NCT02997748</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Preconditioning After Cardiac Surgery</brief_title>
  <acronym>RIPCRenal</acronym>
  <official_title>Remote Ischemic Preconditioning to Prevent Acute Kidney Injury in High Risk Patients After Cardiac Surgery (RIPCRenal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Else Kröner Fresenius Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a well-recognized complication after cardiac surgery with&#xD;
      cardiopulmonary bypass (CPB). The aim of this study is to reduce the incidence of AKI by&#xD;
      implementing remote ischemic preconditioning and to evaluate the dose-response relationship&#xD;
      using the biomarkers urinary [TIMP-2] *[IGFBP7] in high risk patients undergoing cardiac&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) complicates 7-19% of cardiac surgical procedures. The investigators&#xD;
      recently found that remote ischemic preconditioning (RIPC) using transient external&#xD;
      compression of the upper arm prior to cardiac surgery was effective for reducing the&#xD;
      occurrence of AKI (37.5% compared to 52.5% with sham; absolute risk reduction (ARR),15%; 95%&#xD;
      CI, 2.56% to 27.44%; P=0.02). Fewer patients treated with RIPC received renal replacement&#xD;
      therapy (RRT) (5.8% versus 15.8%; ARR, 10%; 95% CI, 2.25% to 17.75%; P=0.01). Moreover, the&#xD;
      investigators found that the effectiveness of this intervention was strongly associated with&#xD;
      the release of cell-cycle arrest biomarkers into the urine. Patients with urinary tissue&#xD;
      inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7&#xD;
      ([TIMP-2]•[IGFBP7]) ≥ 0.5 (ng/ml)(ng/ml)/1000 before surgery had a significantly reduced rate&#xD;
      of AKI compared to patients with lower urinary [TIMP-2]•[IGFBP7] concentration (relative risk&#xD;
      (RR), 67%; 95% CI, 53% to 83%, P&lt;0.001) whereas the biomarker concentrations after surgery&#xD;
      predicted AKI as previously shown. This effect makes sense because cell-cycle arrest is&#xD;
      thought to be part of the protective mechanisms endothelial cells use when exposed to stress.&#xD;
      Stimulating these responses with RIPC should reduce AKI. Importantly, only 56% of patients&#xD;
      treated with RIPC achieved an increase in urine [TIMP-2]•[IGFBP7] to ≥ 0.5, and only in this&#xD;
      group was the intervention effective-patients that did not achieve this level showed no&#xD;
      benefit.&#xD;
&#xD;
      Our goal is to eventually design and conduct a Bayesian 2-stage adaptive design sequence&#xD;
      trial to evaluate the effectiveness of RIPC to prevent AKI in patients undergoing cardiac&#xD;
      surgery. The dimensions of dose include duration, intensity and number of cycles. However,&#xD;
      before this trial can be designed we need to answer 4 questions: i. Do baseline urinary&#xD;
      [TIMP-2]•[IGFBP7] levels predict AKI (enrichment)? ii. Do [TIMP-2]•[IGFBP7] changes elicited&#xD;
      by RIPC predict protection (RIPC efficacy measure)? iii. Is there a dose-response&#xD;
      relationship between RIPC &quot;dose&quot; and [TIMP-2]•[IGFBP7]? iv. Is a dose-escalation RIPC&#xD;
      protocol where doses are increased for non-responders, feasible and safe within the&#xD;
      anesthesia workflow for cardiac surgery cases (practical)?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urinary [TIMP-2]*[IGFBP7]</measure>
    <time_frame>within 12 hours after CPB</time_frame>
    <description>Biomarkers will be measured at different time points after to evaluate the effect of RIPC on [TIMP-2]*[IGFBP7]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AKI within 72 hours</measure>
    <time_frame>72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis within 7 days of surgery</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause-mortality at 90 days</measure>
    <time_frame>90 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis at day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal recovery at day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAKE 90</measure>
    <time_frame>90 days</time_frame>
    <description>major adverse kidney events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cardiac Surgery, Aortocoronary Bypass</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham RIPC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Three cycles of 5- min upper limb sham ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC-Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cycles of 5- min upper limb ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC-Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cycles of 7-min upper limb ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC-Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cycles of 10-min upper limb ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC-Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning (RIPC)</intervention_name>
    <description>3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.</description>
    <arm_group_label>RIPC-Group 1</arm_group_label>
    <arm_group_label>RIPC-Group 2</arm_group_label>
    <arm_group_label>RIPC-Group 3</arm_group_label>
    <arm_group_label>RIPC-Group 4</arm_group_label>
    <arm_group_label>Sham RIPC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are scheduled to undergo cardiac surgery with cardiopulmonary bypass&#xD;
&#xD;
          -  Cleveland Clinic Score &gt;=6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction up to 7 days before surgery&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Off-pump cardiac surgery&#xD;
&#xD;
          -  Preexisting AKI&#xD;
&#xD;
          -  Chronic kidney disease (GFR &lt; 30 ml/min)&#xD;
&#xD;
          -  Kidney transplantation within the last 12 months&#xD;
&#xD;
          -  Peripheral arterial occlusive disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hepatorenal syndrome&#xD;
&#xD;
          -  Sulfonamide or thiazide medication within the last 7 days&#xD;
&#xD;
          -  Participation in another interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Meersch</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Meersch, MD</last_name>
    <phone>+49-251-8347282</phone>
    <email>aki@anit.uni-muenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zarbock, PhD, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>Remote ischemic preconditioning</keyword>
  <keyword>[TIMP-2]*[IGFBP7]</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

